Apieron, Inc. Announces Appointment of Holly McGarraugh as President and Chief Executive Officer
MENLO PARK, Calif., Oct. 8 /PRNewswire-FirstCall/ — Apieron, Inc. (http://www.apieron.com) announced today that its Board of Directors has appointed Holly McGarraugh as president and CEO of the company, effective immediately. Ms. McGarraugh replaces Rich Lotti, who resigned to pursue other business interests.
"The Apieron Board chose Holly for the CEO position because of her strong commercialization experience," said Wende Hutton, Apieron Board member and partner with Canaan Partners. "Holly has made a remarkable contribution to Apieron since she joined the company, and we are confident that she will add considerable value to the company, leading Apieron through commercialization in the asthma therapy marketplace."
Ms. McGarraugh, a 20-year veteran of the consumer medical device industry, joined Apieron as vice president of marketing in January 2008. She was previously vice president of worldwide marketing for in vivo products at Abbott Diabetes Care where she lead commercialization efforts, including clinical acceptance and reimbursement, for continuous glucose monitoring, a new product category. Abbott Labs formed Abbott Diabetes Care by acquiring TheraSense, a start-up where Ms. McGarraugh had been vice president of marketing and professional relations.
"Apieron recently received FDA clearance for the Insight eNO System, for which we are in the process of executing an early commercialization plan," said Holly McGarraugh, CEO of Apieron. "I am looking forward to leading a tremendously talented team focused on building relationships with the therapeutic community to improve the standard of care for people who suffer with asthma."
About Apieron Inc.
Apieron Inc. is a private, venture-backed medical device company based
in Menlo Park, CA that was formed in early 2001 to develop a simple-to-use,
non-invasive monitor for the measurement of exhaled nitric oxide (eNO) for
the management of asthma. The Apieron biosensor technology platform
utilizes a patented technology that allows for the highly sensitive
detection of selected analytes like eNO. Apieron is committed to
collaborating with physicians and patients to develop innovative medical
solutions to improve quality of life and standards of care.
Contact:
Steve DiMattia
(646) 201-5445